PetIQ, Inc. (PETQ)
USD 30.98
(-0.03%)
USD 30.98
(-0.03%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 192.72 Million USD | 5.57% |
| 2022 | 182.56 Million USD | 7.06% |
| 2021 | 170.52 Million USD | 23.23% |
| 2020 | 138.37 Million USD | 34.08% |
| 2019 | 103.2 Million USD | 42.82% |
| 2018 | 72.26 Million USD | 90.63% |
| 2017 | 37.9 Million USD | 19.03% |
| 2016 | 31.84 Million USD | -10.52% |
| 2015 | 35.58 Million USD | 11.88% |
| 2014 | 31.8 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 49.7 Million USD | 18.24% |
| 2024 Q2 | 59.31 Million USD | 19.32% |
| 2023 Q3 | 55.02 Million USD | -0.25% |
| 2023 Q4 | 42.04 Million USD | -23.59% |
| 2023 FY | 192.72 Million USD | 5.57% |
| 2023 Q2 | 55.15 Million USD | 27.31% |
| 2023 Q1 | 43.32 Million USD | 14.78% |
| 2022 Q3 | 45.98 Million USD | -9.11% |
| 2022 FY | 182.56 Million USD | 7.06% |
| 2022 Q1 | 48.23 Million USD | 16.36% |
| 2022 Q4 | 37.74 Million USD | -17.91% |
| 2022 Q2 | 50.59 Million USD | 4.89% |
| 2021 Q1 | 40.67 Million USD | 24.64% |
| 2021 Q2 | 43.14 Million USD | 6.07% |
| 2021 Q3 | 45.25 Million USD | 4.89% |
| 2021 Q4 | 41.45 Million USD | -8.39% |
| 2021 FY | 170.52 Million USD | 23.23% |
| 2020 Q3 | 35.56 Million USD | -7.61% |
| 2020 Q2 | 38.49 Million USD | 21.46% |
| 2020 Q1 | 31.69 Million USD | 9.78% |
| 2020 FY | 138.37 Million USD | 34.08% |
| 2020 Q4 | 32.63 Million USD | -8.24% |
| 2019 Q4 | 28.86 Million USD | -1.63% |
| 2019 FY | 103.2 Million USD | 42.82% |
| 2019 Q3 | 29.34 Million USD | 20.02% |
| 2019 Q2 | 24.45 Million USD | 19.05% |
| 2019 Q1 | 20.53 Million USD | 9.66% |
| 2018 FY | 72.26 Million USD | 90.63% |
| 2018 Q1 | 18.96 Million USD | 80.92% |
| 2018 Q2 | 16.94 Million USD | -10.68% |
| 2018 Q3 | 17.62 Million USD | 4.0% |
| 2018 Q4 | 18.72 Million USD | 6.28% |
| 2017 Q4 | 10.48 Million USD | -2.37% |
| 2017 Q1 | 7.4 Million USD | -1.76% |
| 2017 FY | 37.9 Million USD | 19.03% |
| 2017 Q2 | 9.27 Million USD | 25.28% |
| 2017 Q3 | 10.73 Million USD | 15.76% |
| 2016 Q1 | 8.06 Million USD | 0.0% |
| 2016 Q4 | 7.53 Million USD | -5.09% |
| 2016 Q3 | 7.94 Million USD | -4.34% |
| 2016 Q2 | 8.3 Million USD | 2.96% |
| 2016 FY | 31.84 Million USD | -10.52% |
| 2015 Q1 | 7.88 Million USD | 0.0% |
| 2015 FY | 35.58 Million USD | 11.88% |
| 2014 FY | 31.8 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -2235.248% |
| Alpha Teknova, Inc. | 45.85 Million USD | -320.256% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 1.662% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -329.672% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | -21.052% |
| Cosmos Health Inc. | 26.18 Million USD | -636.131% |
| Journey Medical Corporation | 54.59 Million USD | -253.015% |
| Embecta Corp. | 528.4 Million USD | 63.527% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 29.118% |
| Dynavax Technologies Corporation | 219.14 Million USD | 12.056% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 67.335% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 40.95% |
| PainReform Ltd. | 9.58 Million USD | -1910.904% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1368.44% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1368.44% |
| SCYNEXIS, Inc. | 51.84 Million USD | -271.712% |
| Safety Shot Inc | 12.1 Million USD | -1491.494% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -6179.348% |
| Procaps Group, S.A. | 199.47 Million USD | 3.385% |
| Theratechnologies Inc. | 72.75 Million USD | -164.892% |
| Harrow Health, Inc. | 89.97 Million USD | -114.203% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -1940.282% |
| Biofrontera Inc. | 39.95 Million USD | -382.307% |
| DURECT Corporation | 43.71 Million USD | -340.867% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 63.569% |
| Cronos Group Inc. | 96.7 Million USD | -99.283% |
| OptiNose, Inc. | 85.1 Million USD | -126.464% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 16.973% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -392.236% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 2115.741% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 38.649% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -1880.56% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -347.775% |
| Radius Health, Inc. | 265.92 Million USD | 27.528% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -1292.33% |
| ProPhase Labs, Inc. | 37.85 Million USD | -409.154% |
| Phibro Animal Health Corporation | 260.29 Million USD | 25.96% |
| Procaps Group S.A. | 187.24 Million USD | -2.927% |
| Alvotech | 285.43 Million USD | 32.481% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -1861.578% |
| Viatris Inc. | 5.96 Billion USD | 96.77% |
| Rockwell Medical, Inc. | 15.37 Million USD | -1153.577% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -222.067% |
| SIGA Technologies, Inc. | 22.04 Million USD | -774.313% |
| Tilray Brands, Inc. | 251.35 Million USD | 23.326% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -293.012% |
| Shineco, Inc. | 17.94 Million USD | -973.794% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -4728.823% |
| Incannex Healthcare Limited | 30.05 Million USD | -541.284% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 87.928% |
| Alimera Sciences, Inc. | 62.64 Million USD | -207.666% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -25175.675% |
| Assertio Holdings, Inc. | 368.58 Million USD | 47.712% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -3174.534% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -982.206% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -810.411% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -815.902% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | -16.827% |
| Hempacco Co., Inc. | 7.59 Million USD | -2437.041% |
| Talphera, Inc. | 11.99 Million USD | -1506.845% |
| Alvotech | 285.43 Million USD | 32.481% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | -36.962% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 44.122% |
| Currenc Group, Inc. | 24 Million USD | -702.951% |
| Kamada Ltd. | 45.42 Million USD | -324.261% |
| Indivior PLC | 911 Million USD | 78.845% |
| Evoke Pharma, Inc. | 12.4 Million USD | -1453.026% |
| Flora Growth Corp. | 10.57 Million USD | -1721.77% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -815.902% |
| Evolus, Inc. | 189.75 Million USD | -1.563% |
| HUTCHMED (China) Limited | 436.23 Million USD | 55.82% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | -25.037% |
| Akanda Corp. | 3.48 Million USD | -5432.498% |